BioMarin Pulls EU Hemophilia Gene Therapy Filing, But Is Not Giving Up
Agios’s MAA For Tibsovo also withdrawn
BioMarin plans to resubmit its marketing application for Roctavian to the European Medicines Agency.
You may also be interested in...
BioMarin plans to file for approval of its investigational hemophilia A gene therapy in the EU in June this year but its US filing is not planned until Q2 2022. It will be the company's second attempt at success in both jurisdictions.
BioMarin is planning to resubmit its EU marketing application for Roctavian soon and, as with the previously pulled application, it wants the regulators to fast-track the new filing.
A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.